Kymera Therapeutics (KYMR) EBIT Margin (2019 - 2026)
Kymera Therapeutics' (KYMR) quarterly EBIT Margin came in at 244.88% in Q1 2026, up 9189.0% year-on-year from 2.64% in Q1 2025, and up 92.82% on a QoQ basis from 3411.01% in Q4 2025.
Kymera Therapeutics (KYMR) EBIT Margin (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of EBIT Margin data on file, last reported at 244.88% in Q1 2026.
- On a quarterly basis, EBIT Margin rose 9189.0% year-over-year to 244.88% in Q1 2026; TTM through Mar 2026 was 697.67%, a 22518.0% decrease from a year earlier, with the FY2025 full-year figure at 891.07%, down 33526.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 244.88%, up from 3411.01% in the prior quarter.
- Over the last five years, EBIT Margin for KYMR reached as high as 40.33% in Q4 2023 and fell as low as 3411.01% in Q4 2025.
- Historically, EBIT Margin has averaged 900.2% across 5 years, with a median of 469.92% in 2022.
- On a YoY basis, EBIT Margin climbed as much as 22541 bps in 2025 and fell as far as 231884 bps in 2025.
- Year by year, EBIT Margin stood at 239.36% in 2022, then surged by 83 bps to 40.33% in 2023, then slumped by 2608 bps to 1092.17% in 2024, then sank by 212 bps to 3411.01% in 2025, then surged by 93 bps to 244.88% in 2026.
- Per Business Quant data, the three most recent EBIT Margin figures were 244.88% in Q1 2026, 3411.01% in Q4 2025, and 3347.36% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Kymera Therapeutics | 10.77 Bn | 10.11 Bn | - | -244.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -244.88% |
| Dec 31, 2025 | -3,411.01% |
| Sep 30, 2025 | -3,347.36% |
| Jun 30, 2025 | -736.82% |
| Mar 31, 2025 | -336.77% |
| Dec 31, 2024 | -1,092.17% |
| Sep 30, 2024 | -1,927.93% |
| Jun 30, 2024 | -198.54% |
| Mar 31, 2024 | -562.18% |
| Dec 31, 2023 | -40.33% |
| Sep 30, 2023 | -1,216.35% |
| Jun 30, 2023 | -262.72% |
| Mar 31, 2023 | -478.83% |
| Dec 31, 2022 | -239.36% |
| Sep 30, 2022 | -469.92% |
| Jun 30, 2022 | -354.44% |
| Mar 31, 2022 | -383.84% |
| Dec 31, 2021 | -222.55% |
| Sep 30, 2021 | -140.82% |
| Jun 30, 2021 | -133.54% |